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ABSTRACT We have determined the three-dimensional
structures of the antigen-binding fragment of the anti-digoxin
monoclonal antibody 26-10 in the uncomplexed state at 2.7 A
resolution and as a complex with digoxin at 2.5 A resolution.
Neither the antibody nor digoxin undergoes any significant
conformational changes upon forming the complex. Digoxin
interacts primarily with the antibody heavy chain and is
oriented such that the carbohydrate groups are exposed to
solvent and the lactone ring is buried in a deep pocket at the
bottom of the combining site. Despite extensive interactions
between antibody and antigen, no hydrogen bonds or salt links
are formed between 26-10 and digoxin. Thus the 26-10-digoxin
complex is unique among the known three-dimensional struc-
tures ofantibody-antigen complexes in that specificity and high
affinity arise primarily from shape complementarity.
Digoxin (digoxigenin tridigitoxoside; Structure I) inhibits the
Na+,K+-ATPase and is used in treatment of congestive heart
failure (1). Digoxin is a cardenolide-type steroid with an
a,4-unsaturated lactone ring attached at C-17 and three P(1-+
4)-D-glycoside-linked digitoxoses attached at 0-3. It is a rel-
atively large and rigid hapten, whose internal degrees of free-
dom are limited to rotations about the lactone-cardenolide
bond (C-17 to C-20; Structure I) and about the digitoxose
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linkages (2). Many digoxin congeners of known chemical
structure are available, including several with high-resolution
crystal structures (2). These analogues vary as to the substit-
uents on the steroid rings, the number and type of attached
carbohydrate groups, and the saturation of the lactone ring.
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Anti-digoxin antibodies have been used to measure serum
digoxin levels as a guide to therapy and to treat otherwise
fatal digoxin intoxication (3). Anti-digoxin antibodies com-
plexed with structurally distinct digoxin congeners are also
an excellent model system to study the structural basis of
antibody specificity.
The antibody 26-10 (IgG2a, K light chain) is a murine
monoclonal antibody that exhibits high affinity (1010 M-1) for
digoxin and varying specificity for digoxin congeners (4-6).
Both the intact 26-10 antibody and the 26-10 Fab (antigen-
binding fragment) reverse lethal digoxin toxicity in guinea
pigs (7). Spontaneous and site-directed mutants of26-10 have
been generated (6, 8, 9). The specificities of 26-10 and its
mutants have been characterized for a wide range of digoxin
congeners (6, 8, 9).
We report the three-dimensional structures of the 26-10
Fab fragment at 2.7 A resolution and of the Fab-digoxin
complex at 2.5 A resolution.i¶
MATERIALS AND METHODS
Antibody 26-10 was obtained from A/J mice immunized with
a digoxin-human serum albumin conjugate (4). Purified an-
tibody was cleaved by papain, and the Fab was purified by
using ion-exchange chromatography (10). Crystals of the
26-10 Fab-digoxin complex were grown in the presence of a
3-fold molar excess of digoxin from 16% to 18% (wt/wt)
polyethylene glycol (average Mr = 8000) with 1.7% (vol/vol)
2-methyl-2,4-pentanediol in 10 mM sodium phosphate at pH
7.5 (11). The complex crystals have the symmetry of space
group P2 , with cell dimensions a = 44.2 A, b = 164.4 A, c
= 70.0 L and /3 = 108.40. There are two Fab-digoxin
complexes in the asymmetric unit. The crystals were twinned
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by hemimerohedry, with the (h, k, 0 reflections from one
lattice and the (h, k, -h-) reflections from the other being
spatially overlapped and not resolvable during data collec-
tion. The twin fraction, as estimated by the method of Britton
(12), was highly variable between crystals (11). Data were
collected on a San Diego Multiwire area detector (13) to a
maximum resolution of 2.5 A (Table 1). The structure was
determined by the method of molecular replacement (15)
using data that had been detwinned.
The data set used for the molecular replacement solution
had an estimated twin fraction of 20% and a maximum
resolution of 2.7 A. This data set, after detwinning, was used
for the first cycles of refinement. Subsequently, a different
data set was used for the refinement due to a superior
maximum resolution of 2.5 A. The 2.5 A data set had an
estimated twin fraction in excess of 35%. The structure was
refined by using the program X-PLOR (16). Since the detwin-
ning method significantly reduced the completeness of the
data, a method of refining the structure on the basis of
twinned data was developed. The effects of twinning were
introduced into IFicl, with the twin fraction estimated by
least-squares minimization of the crystallographic residual,
given the known twinning relationship (Table 1) (P.D.J. and
S.S., unpublished results). Electron density maps were cal-
culated using detwinned data. The program CHAIN (17) was
used for electron density map inspection and structure mod-
ification. After the chain trace in the antibody-combining site
was completed and most of the side chains were fitted into
density, a model of digoxin (2) was fitted into a large volume
of unattributed positive difference density in the combining
site. The digitoxose groups were deleted since there was no
clear difference density for them, but it was possible to add
the first digitoxose group back into the model during refine-
ment. No solvent molecules were incorporated into the
model during refinement. The final model had low deviations
Table 1. Data collection and refinement statistics
26-10 Fab-digoxin 26-10 Fab
Data collection
Maximum resolution, A 2.5 2.7
Number of observations 68,345 16,046
Number of reflections 27,121 7998
R merge on intensities*, % 4.8 5.6
(I/o0) 10.9 26.3
Structure refinement
Resolution range, A 8.0-2.5 8.0-2.7
Number of reflectionst 25,135 7326
Number of atoms 6652 3299
Completeness of datat, % 80.0 61.0
R value (uncorrected)§, % 24.3 17.7
R value (corrected)A, % 17.4
Estimated twin fractionll 0.358
rms Abond length, A 0.013 0.014
rms Abond angle 3.20 3.30
rms Adihedrals 28.10 28.30
rms Aimpropers 1.40 1.30
Coordinate error**, A 0.25 0.30
A, Change in.
*7:,{:jjIu - (IV)j)/z:(Ili forj observations of each unique reflection i.
t1F1 > lrpF
tNumber ofreflections used in refinement as a fraction ofthe number
of theoretically observable unique reflections.
§ZIIFobsI - kFca.cj|/7jFobsj; Fobs uncorrected for twinning and F&ca
calculated from model.$Uncorrected Fob,; F,alccorrected for twinning using Fcac: IF(h)caicI
= ((1 - f).F(h)caicl2 - fijF(h')caacI2)u/2, wherefis the estimated twin
fraction, h is the miller index (h, k, l), and h' is (h, k, -h-i).
"Estimated by least-squares minimization (P.D.J. and S.S., unpub-
lished results).
**Luzzati (14).
from ideal stereochemistry and a residual of 0. 171 (corrected
for twinning) for reflections in the range 8.0-2.5 A with El >
laF (Table 1).
Crystals ofuncomplexed 26-10 Fab grew in the presence of
a 3-fold molar excess ofdigoxin and 1.5% (wt/vol) formamide
from 40% polyethylene glycol (average Mr = 200) in 40 mM
imidazole-HCl at pH 7.0. The crystals have the symmetry
of space group P21, with cell dimensions a = 43.8 A, b = 89.3
A, c = 59.2 A, and ,B = 95.9° with one Fab in the asymmetric
unit, as reported (10). The uncomplexed crystal form was not
twinned. We were unable to grow the uncomplexed Fab
crystals in the absence of digoxin. Data were collected on a
Siemens area detector to a maximum resolution of 2.7 A
(Table 1). The structure was determined by molecular re-
placement using the model ofthe 26-10-digoxin complex with
digoxin deleted, split into the immunoglobulin light-chain
variable-domain (VL)/heavy-chain variable domain (VH) and
immunoglobulin light-chain constant domain (CL)/heavy-
chain constant domain 1 (CH1) fragments. Single clear peaks
were observed for both the VL/VH [signal/noise ratio (s/n)
> 1.43] and CL/CH1 (s/n > 1.27) fragments in the "fast
rotation function" (18) using the program MERLOT (19).
Molecular translations were determined by using the program
BRUTE (20), which yielded clear solutions for the Fv fragment
(which consists of the VL and VH domains; s/n > 1.25) and
the combined translation search (s/n > 1.25). The molecular
replacement solution yielded a correlation coefficient of
0.524 on IF2 for data in the 6-4 A range.
The uncomplexed structure was refined using rigid body,
energy minimization, and simulated annealing protocols us-
ing the program X-PLOR (16). Solvent molecules were not
incorporated into the model during refinement due to the
relatively low resolution and incompleteness of data. The
final model had low deviations from ideal stereochemistry
and a residual of 0.177 for reflections in the range 8.0-2.7
A with El > laF (Table 1).
Molecular surfaces and surface areas for the models were
calculated by using the program MS (21) with a 1.6 A probe
radius and extended atom van der Waals radii (22). Pairwise
contacts were determined by using the method of Sheriff et
al. (23) but using extended atom radii (22). Numbering of
residues and designations offramework regions and comple-
mentarity determining regions (CDRs) are according to Ka-
bat et al. (24).
The data and model coordinates of the 26-10 Fab and
Fab-digoxin crystal structures have been deposited in the
Protein Data Bank (25).
RESULTS
Uncomplexed Structure. Crystals of the uncomplexed Fab
were obtained from crystallization solutions that contained
excess digoxin. The excess hapten and the high affinity of
26-10 for digoxin would be expected to give rise to crystals of
Fab-digoxin complex rather than the uncomplexed Fab.
However, the electron density maps did not show convincing
difference density for digoxin, in contrast to that observed
during refinement of the 26-10-digoxin complex. When a
model of the digoxin complex was refined against the un-
complexed Fab data set, the average B factor for digoxin was
41 A2, which is significantly greater than that of the combin-
ing site (12 A2 for residues in contact with digoxin). Since the
crystal apparently contains uncomplexed Fab, either the
effective concentration of digoxin in the crystallization me-
dium must have been reduced, perhaps due to precipitation,
or the affinity is reduced similar to that seen with phospho-
choline binding to crystallized McPC603 (26).
No ordered electron density was observed for the N-ter-
minal residue of the VH domain and the C-terminal residues
of the CL domain in the uncomplexed Fab. Two additional
Immunology: Jeffrey et al.
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residues were added into density extending from the C
terminus of CH1 as alanine residues, but there was no
interpretable side-chain density for these residues. Other
regions with poorly defined electron densities and higher B
factors were residues H25-H31 in VH, H53-H56 in CDR H2,
and H128-H137 in CHl.
Complexed Structure. Digoxin is bound at the center of the
combining site in 26-10, between the VL and VH domains
FIG. 1. (A) Schematic representation of the variable regions of the 26-10-digoxin complex, with Cc, atoms connected by rods. The VL domain
is shown in white, the VH domain is shown in gray, and digoxin is shown as a space-filling atomic representation. Digoxin color coding is dark
gray for carbon atoms and red for oxygen atoms. The CDRs are represented as follows: Li, orange; L2, pale green; L3, pale blue; Hi, purple;
H2, green; H3, blue. (B) Space-filling representation of the 26-10-digoxin complex looking approximately down the interdomain pseudo-dyad
axis of the Fv toward digoxin. Same color scheme as in A is used. (C) Cut-away view of the complex with all of the VH domain except CDR
H3 deleted. The view is approximately perpendicular to the pseudo-dyad axis, looking from VH. (D) Cut-away view of the complex with CDR
L3 and the first two residues of VL removed. The view is approximately perpendicular to the pseudo-dyad axis looking from CDR L3. (E) Dot
surface representation ofthe complex as seen from VL. The red dot surface represents the molecular surface of26-10 atoms buried in the complex.
The yellow dot surface represents the molecular surface of digoxin atoms buried in the complex. Tyr-H47 is immediately to the left of Pro-L96.
(F) Dot surface representation of the complex as seen from CDR H3. This figure was generated by the program RASTER3D written by David
Bacon.
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(Fig. 1A). The long axis of digoxin (from the 0-3 atom to the
C-17 atom) is approximately parallel (inclined by 220) to the
pseudo 2-fold axis that interrelates the VL and VH domains
(Fig. 1A and B). The lactone ring is buried deepest within the
combining site, and the digitoxoses are exposed to solvent
(Fig. 1 C and D). The surface complementarity between
antibody and hapten is closest at the lactone and steroid D
rings and decreases toward the periphery of the binding site.
Correspondingly, the atomic B factors for digoxin are lowest
at the lactone ring (10 A2) and increase toward the digitoxose
(49 A2). The mean B factor for the lactone ring atoms is
comparable to that for the 26-10 residues in the combining site
that contact digoxin (13 A2). Digoxin is sandwiched between
the aromatic rings of Tyr-H33, Tyr-H50, and Trp-H100 (Fig.
1 D and F), but the complementarity is much less close in
other regions: there are significant gaps between the surfaces
in the complex around the hydroxyl groups at positions 12
and 14 on digoxin (Fig. 1 C and E).
As with the uncomplexed Fab, the N terminus of VH and
the C terminus ofCL were disordered. The same regions that
were disordered in the uncomplexed Fab were disordered in
the complex.
When the individual domains from two 26-10-digoxin com-
plexes in the asymmetric unit are compared, the root-mean-
square (rms) deviations on superimposing Ca atoms in each
domain were 0.5 A for VL, 0.8 A for VH (0.6 A excluding
the disordered H25-H31 loop), 0.6 A for CL, and 0.9 A for
CH1 (0.6 A excluding the disordered H127-H137 loop).
Superimposing the two copies of digoxin gave an rms devi-
ation of 0.2 A on all steroid ring carbon atoms (C-1 to C-17).
Differences Between Complexed and Uncomplexed Fab. No
significant conformational changes are observed in the com-
bining site between the complexed and uncomplexed Fab.
The largest conformational change in the CDRs is in a region
at the top ofCDR H3 (residues H97-H99) that does not make
contact with digoxin in the complex and that is involved in a
crystal contact in the uncomplexed Fab structure. Residues
H97-H99 have higher average B factors than the rest ofCDR
H3 in both complexed and uncomplexed structures. The
residues in CDR H3 that make contact with digoxin (Table 2)
show no significant deviations between the complexed and
uncomplexed Fabs. The rms deviations on superimposing Ca
atoms from the Fab domains ofthe uncomplexed and the first
of the two independent 26-10-digoxin complexes are 0.5 A for
VL, 0.7 A for VH (0.6 A excluding the disordered H25-H31
region), 0.5 A for CL, and 0.7 A for CHi. The differences in
VL/VH and CL/CH1 pairings between complexed and uncom-
Table 2. Contacts between Fab and hapten
plexed forms are less than 2.50, compared to less than 1.00
between the two complexes.
Conformational Changes in the Hapten. The position of the
lactone ring of digoxin in the complex is flipped by 1800 about
the C-17--C-20 bond, relative to the small-molecule crystal
structure of digoxin (2). The orientation of the lactone is the
same as observed in a number of cardiac glycoside crystal
structures (2). The close complementarity around the lactone
ring makes the complex specific for only one of the two
possible lactone conformations. No electron density is seen
for the second and third (outermost) carbohydrate groups of
digoxin. No other significant conformational changes are
observed in the antigen. The rms deviation for all carbon
atoms in the steroid rings between the digoxin in 26-10-
digoxin and the structure of Go et al. (2) is 0.3 A, which is
comparable to the rms differences between the two copies of
the complex (see above).
Interactions Between 26-10 and Digoxin. The pairwise con-
tacts between 26-10 and digoxin in the complex are summa-
rized in Table 2. There are no hydrogen bonds or charged
group interactions between 26-10 and digoxin: all the contacts
are nonpolar. Sixty-one pairwise contacts involve 10 anti-
body residues from four CDRs and one framework region and
19 digoxin atoms from all four steroid rings and the lactone.
Additionally, the Fab residues His-L27d and Asn-L34 from
CDR Li, the framework residue Tyr-L36, and the digitoxose
group on digoxin are partially buried on complexation. CDR
L2 is not directly involved in the binding of digoxin. CDR H3
makes the most extensive interactions with the hapten,
including the side chain of Trp-HlOO that extends between
digoxin and CDR Li. In addition to the CDRs, the framework
residue Tyr-H47 makes contacts with the hapten, and frame-
work residue Tyr-L36 is partially buried on complex forma-
tion. Residue Tyr-H47 is a conserved Trp in 93% of mouse
antibodies (24), but Trp could not be accommodated in the
complex without disrupting the complementarity between
the Fab and digoxin and without eliminating the hydrogen
bond between the side chains of Asn-H35 and Tyr-H47. The
majority of the pairwise contacts between Fab and hapten
(Table 2) involve four aromatic side chains from the Fab
(Tyr-H33, Tyr-H47, Tyr-H50, and Trp-H100; 36 of 62 con-
tacts) and the lactone and D rings of digoxin (48 of 61
contacts). The monodigitoxose does not make any contacts
with the Fab, although 26 A2 Of its molecular surface is buried
in the complex (Table 2).
DISCUSSION
The three-dimensional structure of the 26-10-digoxin com-
plex allows us to qualitatively explain the fine specificity of
Buried Buried
Contacting Pairwise area, Contacting Pairwise area,
Region residues contacts A2 Digoxin region Region atoms contacts A2 Fab region
Fab to hapten Hapten to Fab
CDR Li 0 5 Digitoxose 0 26
CDR L3 Thr-L91, Pro-L96 9 92 Ring D, Ring A C-2, C-3, C4 4 36 CDRs Hi, H2
lactone
CDR Hi Tyr-H33, Asn-H35 13 55 Rings A, C, D; Ring B C-6, C-7, C-19 8 36 CDRs Hi, H3
lactone
FR2 VH Tyr-H47 6 19 Ring D; Ring C C-12, 0-12 3 37 CDRs L3, H2
lactone
CDR H2 Tyr-H50 6 74 Rings A, C, D Ring D 0-14, C-15, C-16, 17 75 CDRs L3, Hi, H2,
C-17, C-18 H3; FR2 VH
CDR H3 Ser-H95, Trp-HiOO, 26 126 Rings B, D; Lactone C-20, C-21, 0-21 27 78 CDRs L3, Hi, H3;
Ala-HlOOa, Met-HlOOb lactone C-22, C-23, 0-23 FR2 VH
Total 59 383 Total 59 274
Calculation of pairwise contacts and buried surface area is described in Materials and Methods. Noncontacting 26-10 residues contribute 79
A2 of the total buried surface area. Noncontacting digoxin atoms contribute 39 A2 of the total buried surface area. FR2, framework region 2.
CDRs H1-H3 refer to CDRs 1-3 in the immunoglobulin heavy chain; CDRs Li and L3 refer to CDRs 1 and 3 in the light chain.
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26-10 for many of the digoxin congeners whose binding
affinity has been measured (6). The 26-10 antibody does not
recognize the presence or absence of the digitoxose groups in
digoxin, and the affinities for the mono-, bis- and tridigitox-
ose forms are identical. The lack of recognition of the
carbohydrate corresponds to the limited interactions be-
tween the digitoxose and Fab in the complex and the disorder
of the second and third digitoxose groups. However, the
26-10 antibody recognizes the presence and type of carbo-
hydrate groups on digoxin congeners with substituents at
C-16 and C-12 that have reduced binding affinities for 26-10
(6). The complex structure does not explain the recognition
of carbohydrate in these cases, although it is possible that the
orientation of the glycoside in the binding site may be slightly
different, allowing greater interaction between the carbohy-
drate and the Fab.
The 26-10 antibody binds digitoxigenin (which lacks the
12,&OH of digoxigenin) with equal affinity to digoxigenin.
Thus the 123-OH is not a major determinant of fine speci-
ficity, despite the two contacts made between the 12,&OH in
digoxin and Pro-L96 (Table 2). The 1213-OH is only partially
accessible to solvent in the complex, and it is possible that the
energy gained from interactions between antibody and anti-
gen is offset by the necessity of partially desolvating this
group on forming the complex.
The close complementarity between 26-10 and digoxin at
the 16 position in the D-ring of digoxin causes 26-10 to
recognize substituents at C-16. The 26-10 antibody binds
gitoxin (16,1OH) 5-fold less well than digoxin (6). The small
decrease in affinity suggests that the complex is able to
rearrange slightly in this region, and interactions between the
OH and the side chain of residue Asn-H35 may play a role in
limiting the affinity loss. Larger substituents at C-16 would
cause more disruption of the combining site, and congeners
with formyl and acetyl groups at C-16 have markedly reduced
affinities (6).
The crystal structures of Fab in complex with antigen and
hapten (reviewed in ref. 27) have shown that antigen recog-
nition is achieved by a combination of shape complementar-
ity, hydrogen bonding, and charged group complementarity.
In contrast to the structures of these complexes, and despite
the high affmity constant for digoxin (1010 M-1), there are no
hydrogen-bond or charged group interactions between 26-10
and digoxin. Thus specificity and affinity must arise solely
from shape complementarity. Nevertheless, there are polar
groups on the Fab and the hapten within the combining site.
The polar groups are stabilized either by hydrogen bonds
within the Fab or by accessibility to bulk solvent. The only
polar groups that are not stabilized by interactions with
solvent or other polar residues are the lactone ring 0-21 and
0-23 oxygen atoms of digoxin. Although there are potential
hydrogen-bond donors in the proximity of 0-21, none are
closer than 3.5 A. The only neighbor of 0-21 that has
an acceptable geometry for hydrogen bonding is Ser-H95 OV,
which already makes a 2.9 A hydrogen bond with the
side-chain amide oxygen of Asn-H35 but is 3.5 A away from
0-21. Atom 0-23 also makes no hydrogen bonds, although
the more distant side-chain atoms of Tyr-L36 OH (3.9 A) and
Asn-L34 N82 (4.2 A) may have some role in stabilizing the
partial negative charge on 0-23 in what appears to be a quite
hydrophobic environment.
In common with other antibody-antigen complexes (27),
the complementarity between the solvent-accessible surfaces
of digoxin and 26-10 is imperfect, even in regions that are in
contact. However, there are no cavities buried in the com-
plex that are large enough to contain a solvent (water)
molecule. All of the volumes that are large enough to contain
solvent are accessible to bulk solvent (in particular the
regions around 0-12 and 0-14 on digoxin). There is no
electron density in the combining site that is compatible with
a well-ordered water molecule making bridging hydrogen
bonds between antibody and hapten, and none of the polar
groups on residues making contacts with the hapten have an
additional ordered water molecule bound. The imperfect
complementarity is sufficient to exclude water from the
interface between antibody and antigen but may reduce the
overall energetic contribution of nonbonded interactions,
which decay rapidly with distance. This suggests that the
displacement of water ordered at the surface of digoxin,
rather than dispersion forces, is the dominant term in the high
affinity of 26-10 for digoxin. The rigidity of the hapten (2) and
the aromatic rings in the combining site of the Fab may
enhance this effect, as fewer degrees of freedom are lost on
immobilizing the hapten than would be the case for a more
flexible antigen. The hydrogen-bonding network in the Fab
may further reduce the mobility of smaller side chains in the
combining site. If the displacement of ordered water in the
combining site is the cause of the high affinity of 26-10 for
digoxin, in the same way as the hydrophobic effect in protein
folding, then we would predict a large entropic contribution
to the free energy of binding when the thermodynamics of
hapten binding by the antibody are measured.
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